# US 2019/0002465 A1 · Compounds as modulators of ror gamma

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0002465 A1
- Document ID: US20190002465A1
- Status: Published application
- Kind: A1
- Application number: 16/123,139
- Filed: 2018-09-06
- Published: 2019-01-03
- Earliest claimed: 2014-04-14
- Assignees: Boehringer Ingelheim International GmbH
- Applicants: Boehringer Ingelheim International GmbH
- Inventors: Johanna BAKONYI; Steven Richard BRUNETTE; Delphine COLLIN; Robert Owen HUGHES; Xiang LI; Shuang LIANG; Robert SIBLEY; Michael Robert TURNER; Lifen WU; Qiang ZHANG
- Web page: https://patentgrep.com/patent/US20190002465A1

## CPC

- C07D 475/00: Heterocyclic compounds containing pteridine ring systems
- A61K 31/33: Heterocyclic compounds
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/02: Nasal agents, e.g. decongestants
- A61P 11/06: Antiasthmatics
- A61P 13/12: of the kidneys
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/04: Antipruritics
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- C07D 475/10: with an aromatic or hetero-aromatic ring directly attached in position 2
- C07D 487/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention encompasses compounds of the formula (I) wherein the variables are defined herein which are suitable for the modulation of RORγ and the treatment of diseases related to the modulation of RORγ. The present invention also encompasses processes of making compounds of formula (I) and pharmaceutical preparations containing them.

## Claims

### Claim 1

A compound of formula (I)
wherein:
R1 is:
—CN;
—S(O)nR6;
—S(O)nNR7R8;
—S(O)(NR9)R6;
—N(R9)C(O)R6;
—N(R9)C(O)OR6;
—N(R9)S(O)nR6;
—C(O)OR9;
—C(O)NR7R8; or
—C(O)R9; or
R6, R7, R8 or R9 of R1 may be cyclized onto W to form a ring; and
R2 and R3 are each independently:
(A) —H;
(B) C1-3 alkyl optionally substituted with one, two or three groups selected from:
a) C3-6 cycloalkyl;
b) —OR9;
c) —CN;
d) —CF3;
e) -halo;
f) —C(O)OR9;
g) —C(O)N(R9)2;
h) —S(O)nR9; and
i) —S(O)nNR7R8; or
10-C3-6 cycloalkyl;
11-C3-6 heterocyclyl; or
R2 and R3 are taken together with the carbon to which they are attached to form a C3-6 carbocyclic ring; or
R2 and R3 are taken together with the carbon to which they are attached to form a C3-6 heterocyclic ring; or
R2 or R3 may be cyclized onto W to form a ring;
R4 is:
(A) C1-6 alkyl optionally substituted with one, two or three groups selected from:
a) C3-6 cycloalkyl;
b) C3-6 heterocyclyl;
c) —OR9;
d) —CN;
e) —S(O)nR9;
f) -halo; and
g) —CF3; or
(B) C3-12 cycloalkyl optionally substituted with one, two or three groups selected from:
a) C1-6 alkyl;
b) —OR9;
c) —CN;
d) —S(O)nR9;
e) -halo; and
f) —CF3; or
(C) aryl, heteroaryl or heterocyclyl each optionally substituted with one, two or three groups selected from:
a) C1-6 alkyl;
b) C3-6cycloalkyl;
c) —OR9;
d) —CN;
e) —S(O)nR9;
f) -halo; and
g) —CF3;
R5 is aryl, heteroaryl, heterocyclyl or C3-12 cycloalkyl each optionally substituted with one, two or three groups selected from:
(A) C1-6 alkyl, C3-6 cycloalkyl or C3-6 heterocyclyl each optionally substituted with one, two or three groups selected from:
a) C3-6 cycloalkyl;
b) C3-6 heterocyclyl;
c) —OR9;
d) —CN;
e) —S(O)nNR7R8
f) —S(O)nR9;
g) -halo; and
h) —CF3; or
(B) —OR9;
(C) —CN;
(D) —CF3;
(E) -halo;
(F) —S(O)nNR7R8;
(G) —S(O)nR9; and
(H) —NR7R8;
W is aryl, heteroaryl, heterocyclyl, C3-12 cycloalkyl, or alkynyl each optionally substituted with one or two groups selected from:
a) C1-6 alkyl;
b) C3-6 cycloalkyl;
c) —OR9;
d) —CN;
e) —CF3;
f) -halo;
g) —NR7R8;
h) —C(O)OR9; and
i) —C(O)N(R9)2;
R6 is selected from:
(A) —OH;
(B) C1-6 alkyl optionally substituted with one or two groups selected from:
a) C3-6cycloalkyl;
b) —OR9;
c) —CN;
d) —CF3; and
e) -halo;
10-C3-6 cycloalkyl; and
11-CF3;
R7 and R8 are independently selected from:
(A) —H;
(B) C1-3 alkyl optionally substituted with one or two groups selected from:
a) C3-6cycloalkyl;
b) —OR9;
c) —CN; and
d) -halo; and
(C) C3-6cycloalkyl; or
R7 and R8, together with the nitrogen to which they are bonded, form a saturated ring with 3-6 carbon atoms wherein one carbon atom in said saturated ring may be optionally replaced by —O—, —NR9— or —S(O)n—;
R9 is selected from;
(A) —H;
(B) C1-3 alkyl optionally substituted with one or two groups selected from:
a) C3-6cycloalkyl;
b) —OR9;
c) —CN;
d) —CF3
e) -halo; or
(C) C3-6cycloalkyl; and
n is 0, 1 or 2;
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

A compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof, wherein:
R1 is:
—CN,
—S(O)nR6,
—S(O)nNR7R8;
—N(H)S(O)nR6; or
—S(O)(NH)R6; and
wherein:
R6 is:
(A) C1-3 alkyl optionally substituted with one or two groups selected from:
a) C3-6cycloalkyl;
b) —OR9; and
c) —CN; or
(B) C3-6cycloalkyl;
R7 and R8 are each independently:
(A) —H; or
(B) C1-3 alkyl; and
R9 is selected from;
(A) —H;
(B) C1-3 alkyl; or
(C) C3-6cycloalkyl; and
n is 1 or 2.

### Claim 3 (depends on 1)

A compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof, wherein:
R1 is:
—S(O)nR6,
—S(O)nNR7R8, or
—S(O)(NH)R6; and
wherein:
R6 is:
(A) C1-3 alkyl optionally substituted with one or two groups selected from:
a) C3-6cycloalkyl;
b) —OR9; and
c) —CN; or
(B) C3-6cycloalkyl;
R7 and R8 are each independently:
(A) —H; or
(B) C1-3 alkyl; and
R9 is selected from:
(A) —H;
(B) C1-3 alkyl; or
(C) C3-6cycloalkyl; and
n is 1 or 2.

### Claim 4 (depends on 1)

A compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof, wherein:
R1 is —S(O)nR6, —S(O)nNR7R8 or —S(O)(NH)R6; and
R6 is C1-3 alkyl; and
R7 and R8 are each independently:
(A) —H; or
(B) C1-3 alkyl; and
n is 2.

### Claim 5 (depends on 1)

A compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof, wherein:
R2 and R3 are each independently selected from:
(A) —H;
(B) C1-3 alkyl optionally substituted with one, two or three groups selected from:
a) C3-6 cycloalkyl;
b) —OR9; or
c) -halo; or
R2 and R3 are taken together with the carbon to which they are attached to form a C3-6 carbocyclic ring; or
R2 and R3 are taken together with the carbon to which they are attached to form a C3-6 heterocyclic ring; and
R9 is selected from:
(A) —H; and
(B) C1-3 alkyl.

### Claim 6 (depends on 1)

A compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof, wherein:
R2 and R3 are each independently selected from H and C1-3 alkyl.

### Claim 7 (depends on 1)

A compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R2 and R3 are H.

### Claim 8 (depends on 1)

A compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof, wherein:
R4 is:
(A) C1-6 alkyl optionally substituted with one, two or three groups selected from:
a) C3-6 cycloalkyl;
b) a 4, 5 or 6-membered heterocyclyl;
c) —OR9;
d) —CN;
e) -halo; and
f) —CF3; or
(B) C3-6 cycloalkyl optionally substituted with one, two or three groups selected from:
a) C1-6 alkyl;
b) —OR9;
c) —CN;
d) -halo; and
e) —CF3; and
wherein one carbon in said C3-6 cycloalkyl may be optionally replaced by —O—;
(C) Phenyl; or
(D) a 4, 5 or 6-membered heterocyclyl; and
R9 is selected from:
(A) —H; and
(B) C1-3 alkyl.

### Claim 9 (depends on 1)

A compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof, wherein:
R4 is:
(A) C1-6 alkyl optionally substituted with one or two groups selected from:
a) C3-6cycloalkyl;
b) a 4, 5, or 6-membered heterocyclyl;
c) —OR9;
d) —CN;
e) -halo; and
f) —CF3; or
(B) C3-6 cycloalkyl optionally substituted with one, two or three groups selected from:
a) C1-6 alkyl;
b) —OR9;
c) —CN;
d) -halo; and
e) —CF3, or
(C) Phenyl; or
(D) a 5 or 6-membered heterocyclyl; and
R9 is C1-3 alkyl.

### Claim 10 (depends on 1)

A compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof, wherein:
R4 is:
(A) C1-6 alkyl optionally substituted with one or two groups selected from C3-6cycloalkyl, halo, —CF3, and C1-3 alkoxy; or
(B) C3-6 cycloalkyl optionally substituted with one or two groups selected from C1-6 alkyl, —CF3, and halo; or
(C) a 5-membered heterocyclyl.

### Claim 11 (depends on 1)

A compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof, wherein:
R5 is aryl, heteroaryl or heterocyclyl, each optionally substituted with one, two or three groups selected from:
a) C1-6 alkyl;
b) C3-6cycloalkyl;
c) —OR9;
d) —CN;
e) —CF3;
f) -halo; and
g) —NR7R8, and
R7, R8 and R9 are each independently selected from:
(A) —H; and
(B) C1-3 alkyl.

### Claim 12 (depends on 1)

A compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof, wherein:
R5 is:
(A) phenyl optionally substituted with one, two or three groups selected from:
a) C1-6 alkyl;
b) C3-6cycloalkyl;
c) —OR9;
d) —CN;
e) —CF3; and
f) -halo; or
(B) a 5 or 6-membered heteroaryl optionally substituted with one, two or three groups selected from:
a) C1-6 alkyl;
b) C3-6 cycloalkyl;
c) —OR9;
d) —CN;
e) —CF3;
f) -halo; and
g) —NR7R8; and
R7, R8 and R9 are each independently selected from:
(A) —H; and
(B) C1-3 alkyl.

### Claim 13 (depends on 1)

A compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof, wherein:
R5 is pyridinyl or pyrimidinyl each optionally substituted with one, two or three groups selected from:
a) C1-6 alkyl;
b) C3-6cycloalkyl;
c) —OR9;
d) —CF3; and
e) —NR7R8; and
R7 and R8 are each independently selected from:
(A) —H;
(B) C1-3 alkyl; and
R9 is C1-3 alkyl.

### Claim 14 (depends on 1)

A compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof, wherein:
R5 is pyrimidinyl optionally substituted with one or two groups selected from:
a) C1-3 alkyl;
b) C3-5 cycloalkyl;
c) C1-3 alkoxy; and
d) —CF3.

### Claim 15 (depends on 1)

A compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof, wherein:
W is phenyl, pyridinyl, pyrimidinyl, piperidinyl, piperizinyl, pyrazinyl or C3-12 cycloalkyl, each optionally substituted with one or two groups selected from:
a) C1-6 alkyl;
b) C3-6cycloalkyl;
c) —OR9;
d) —CN;
e) —CF3;
f) -halo;
g) —NR7R8
h) —C(O)OR9; and
i) —C(O)N(R9)2;
R7, R8 and R9 are each selected from:
(A) —H; and
(B) C1-3 alkyl.

### Claim 16 (depends on 1)

A compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof, wherein W is phenyl, pyridinyl, pyrimidinyl or piperidinyl.

### Claim 17 (depends on 1)

A compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof, wherein:
R1 is:
—S(O)nR6,
—S(O)nNR7R8, or
—S(O)(NH)R6;
R2 and R3 are each independently selected from:
(A) —H; and
(B) C1-3 alkyl;
R4 is:
(A) C1-6 alkyl optionally substituted with one or two groups selected from:
a) C3-6 cycloalkyl;
b) a 4, 5, or 6-membered heterocyclyl;
c) —OR9;
d) —CN;
e) -halo; and
f) —CF3;
(B) C3-6 cycloalkyl optionally substituted with one, two or three groups selected from:
a) C1-6 alkyl;
b) —OR9;
c) —CN;
d) -halo; and
e) —CF3;
(C) Phenyl; or
(D) a 5 or 6-membered heterocyclyl;
R5 is:
(A) phenyl optionally substituted with one or two groups selected from:
a) C1-6 alkyl;
b) C3-6 cycloalkyl;
c) —OR9;
d) —CN;
e) —CF3; and
f) -halo; or
(B) Pyridinyl or pyrimidinyl each optionally substituted with one, two or three groups selected from:
a) C1-6 alkyl;
b) C3-6cycloalkyl;
c) —OR9;
d) —CN;
e) —CF3;
f) -halo; and
g) —NR7R8; and
W is phenyl, pyridinyl, pyrimidinyl, piperidinyl or C3-12 cycloalkyl, each optionally substituted with one or two groups selected from:
a) C1-6 alkyl;
b) C3-6 cycloalkyl;
c) —OR9;
d) —CN;
e) —CF3;
f) -halo;
g) —NR7R8
h) —C(O)OR9; and
i) —C(O)N(R9)2;
R6 is:
(A) C1-3 alkyl optionally substituted with one or two groups selected from:
a) C3-6 cycloalkyl;
b) —OR9 and
b) —CN; or
(B) C3-6cycloalkyl;
R7, R8 and R9 are each independently:
(A) —H; or
(B) C1-3 alkyl; and
n is 2.

### Claim 18 (depends on 1)

A compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof, wherein:
R1 is —S(O)nR6 or —S(O)nNR7R8; and
R2 and R3 are H;
R4 is:
(A) C1-6 alkyl optionally substituted with one or two groups selected from C3-6 cycloalkyl, —CF3, and C1-3 alkoxy; or
(B) C3-6 cycloalkyl optionally substituted with one or two groups selected from C1-6 alkyl, —CN, and halo; or
(C) 5-membered heterocyclyl;
R5 is pyrimidinyl optionally substituted with one, two or three groups selected from:
a) C1-6 alkyl;
b) C3-6 cycloalkyl;
c) —OR9;
d) —CF3; and
e) —NR7R8;
W is phenyl, pyridinyl, pyrimidinyl or piperidinyl;
R6 is C1-3 alkyl;
R7, R8 R9 are each independently:
(A) —H; or
(B) C1-3 alkyl; and
n is 2.

### Claim 19 (depends on 18)

A compound of formula (I) according to claim 18, or a pharmaceutically acceptable salt thereof, wherein:
R5 is pyrimidinyl optionally substituted with one or two groups selected from:
a) C1-3 alkyl;
b) C3-5 cycloalkyl; and
c) C1-3 alkoxy; and
W is phenyl, pyridinyl, pyrimidinyl or piperidinyl.

### Claim 20

A compound selected from the compounds in the following table:
Example
Structure
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
or a pharmaceutically acceptable salt thereof.

### Claim 21 (depends on 1)

A pharmaceutical composition comprising a compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.

### Claim 22 (depends on 1)

A method for treating an autoimmune disease or allergic disorder in a patient comprising administering to said patient a therapeutically effective amount of a compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 23 (depends on 22)

A method according to claim 22, wherein the autoimmune disease or allergic disorder is selected from rheumatoid arthritis, psoriasis, systemic lupus erythromatosis, lupus nephritis, scleroderma, asthma, allergic rhinitis, allergic eczema, multiple sclerosis, juvenile rheumatoid arthritis, juvenile idiopathic arthritis, type I diabetes, inflammatory bowel disease, graft versus host disease, psoriatic arthritis, reactive arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, uveitis and non-radiographic spondyloarthropathy.
